Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashish Shah

Internal Medicine Eden, NC Medical Doctor

NPI 1730287020 CMS profile 33692

405 Thompson St, Eden, NC 27288

Open in the dashboard

General payments

$4,843

308 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashish Shah of Eden, NC is reported in the CMS Open Payments database as having received $4,843 across 308 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,031 53
2024 General $841 42
2023 General $318 13
2022 General $31 2
2021 General $162 11
2020 General $1,087 88
2019 General $1,373 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashish Shah
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ashish Shah were reported at $1,031. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ashish Shah Internal Medicine median Middle half National median
2019 $1,373 $159 $48–$570 $163
2020 $1,087 $119 $33–$402 $114
2021 $162 $135 $37–$521 $132
2022 $31 $141 $42–$496 $149
2023 $318 $149 $45–$519 $160
2024 $841 $154 $47–$537 $164
2025 $1,031 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,029 45 payments
  2. Novo Nordisk Inc $381 51 payments
  3. GlaxoSmithKline, LLC. $371 24 payments
  4. Lilly USA, LLC $359 23 payments
  5. AbbVie, Inc. $230 13 payments
  6. Amgen Inc. $167 13 payments
  7. Pfizer Inc. $162 12 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $153 10 payments
  9. Astellas Pharma US Inc $142 11 payments
  10. Sanofi-Aventis U.S. LLC $140 9 payments
  11. Other $1,709 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,823 307 payments
  2. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $478 10 payments
  2. SYMBICORT $338 7 payments
  3. Ozempic $302 39 payments
  4. TRELEGY ELLIPTA $273 17 payments
  5. BEVESPI AEROSPHERE $248 7 payments
  6. RYBELSUS $221 30 payments
  7. BREZTRI $196 9 payments
  8. JARDIANCE $190 12 payments
  9. BRILINTA $190 3 payments
  10. BYDUREON $167 1 payment
  11. Other $4,644 318 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 216 drugs

Part D claims

19,385

Median for Internal Medicine: 777

Drug cost

$1,463,166

Median for Internal Medicine: $73,373

Branded share of claims

20.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 108 $181,432
Eliquis Apixaban Brand 204 $172,812
Farxiga Dapagliflozin Propanediol Brand 141 $134,447
Jardiance Empagliflozin Brand 140 $132,270
Mounjaro Tirzepatide Brand 85 $119,355
Myrbetriq Mirabegron Brand 116 $58,846
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 59 $48,608
Tresiba Flextouch U-200 Insulin Degludec Brand 50 $48,099
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 47 $41,824
Tresiba Flextouch U-100 Insulin Degludec Brand 46 $37,689

The 10 drugs with the highest cost, of 216 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$256,706

Of which drugs: $10,393

Medicare patients

426

Average age 76

Services billed

8,917

253 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 38%
Arthritis 38%
Chronic kidney disease 29%
COPD 23%
Ischemic heart disease 21%
Depression 21%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 97 97 $7,937
Injection, methylprednisolone acetate, 40 mg J1030 Office 21 26 $66
Injection, methylprednisolone acetate, 1 mg J1010 Office 76 226 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $67
$67 141 —
JARDIANCE
  • Lilly USA, LLC $46
  • Boehringer Ingelheim Pharmaceuticals, Inc. $16
$63 140 —
VRAYLAR
  • AbbVie, Inc. $47
$47 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $36
$36 59 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record